الصفحة 1
الصفحة 1
Hepatitis Delta Virus ; Vol. 307
Since its discovery nearly 30 years ago, hepatitis delta virus (HDV) has continued to surprise and fascinate. At 1,680 nucleotides the HDV genome is the smallest known to infect man. It is unique among animal viruses, the closest known relatives being plant viroids. To compensate for its limited protein coding capacity, HDV relies heavily on host functions and on structural features of its circular RNA genome. HDV infection depends on hepatitis B virus as a helper, and increases the severity of liver disease caused by HBV alone. There is currently neither an effective HDV vaccine nor a generally accepted useful therapy for HDV infection. This volume encompasses recent developments in HDV research, from molecular virology to genetics to experimental investigation of new therapeutic and vaccine candidates.
Drug interactions in infectious diseases : Antimicrobial drug interactions
Delivers a quick clinical resource that distills relevant drug interactions by antimicrobial drug class. The book provides informative tables on specific drug-drug interactions that include the degree and severity of the expected interaction. A mechanistic basis for drug-drug interactions is also provided to link observed interactions to pharmacologic characteristics of key drug classes. This complete resource is organized by major antibacterial, antimycobacterial, antiviral, antifungal, antimalarial, and antiprotozoal class. In line with current innovations in antimicrobial drug development, a distinct chapter on the pharmacologic management of drug interactions in hepatitis B virus (HBV) and hepatitis C virus (HCV)-related infections is included. Two new chapters are dedicated to the management of human immunodeficiency virus (HIV) drug-drug interactions given the breadth of antiretroviral class-specific effects. This comprehensive review of known drug interactions and strategies to manage them is an invaluable resource to all health care practitioners.
Congenital torch infections : torch panel
TORCH is a group of infections that can be passed from the pregnant mother to her fetus through the placenta. TORCH, includes Toxoplasmosis, Other (syphilis, varicella-zoster, parvovirus B19, Hepatitis B), Rubella, Cytomegalovirus (CMV), and Herpes infections are some of the most common infections associated with congenital anomalies. Most of the TORCH infections have serious fetal consequences and there has no impact on fetal outcome. In the present article, we wanted to discuss about the causative agents/organism, mode of infection, symptoms, treatment, vaccination, available molecular biological techniques and public awareness regarding this infection, Our objective in this project is to assess the awareness of and knowledge about mother-to-child infections and prevention
Mass Vaccination : Global Aspects - Progress and Obstacles
Mass immunization is the blitzkrieg of vaccination practice. It serves to rapidly protect populations, both because of the high coverage achieved and because of the herd immunity thereby induced. However, as in war, mass immunization campaigns must be conducted intelligently, with careful strategy and strong attention to logistics of supply and deployment. If conducted badly, mass immunization may fail or even be counter-productive. In this volume, some of the most successful practitioners of mass im- nization tell us about its art and science. David Heymann and Bruce Aylward of WHO begin the book with a theoretical and practical overview of mass immunization. Michael Lane, who participated in the successful effort to eradicate smallpox relates how this was done using mass vaccination and other strategies. Application of mass immunization by the US military is c- ered by John Grabenstein and Remington Nevin, who have a large experience in these matters. Karen Noakes and David Salisbury recount the striking s- cesses of mass immunization in the United Kingdom. The global control of the clostridia that produce diphtheria toxin is described by Charles Vitek. Hepa- tis A is decreasing dramatically under the impact of large-scale vaccination, as Francis André illustrates. The French experience with Hepatitis B vac- nation has been mixed, and François Denis and Daniel Levy-Bruhl explain the circumstances. In?uenza vaccination is an annual example of large-scale campaigns, the complexity of which is recounted by Benjamin Schwartz and Pascale Wortley.
Comparative Hepatitis
This volume reviews today’s knowledge about hepatitis with emphasis on comparative aspects between hepatitis in humans and animals, but also between different etiological agents. This particular viewpoint makes the book relevant for scientists from both human and veterinary medicine, gastroenterologists, pathologists, virologists and students of human and veterinary medicine.
Cancer drug safety and public health policy : A changing landscape
Description and analysis of recent developments and current trends in health policy with regard to cancer drug safety. Opens with an overview of pharmacovigilance for cancer blockbuster drugs, covering both general considerations and efforts to develop a structured framework for the identification and reporting of adverse drug reactions (ADRs). A number of important examples of serious ADRs to hematology and oncology drugs are then reviewed, with evaluation of the lessons learned and the policy implications of the ensuing legal cases and their settlements. Further, the difficulty of reporting such blockbuster side effects in the medical literature is explored in an empirical study. Significant advances have been achieved in analytic methods for the identification of ADRs, and here there is a particular focus on the value of optimal discriminant analysis. Finally, the impacts on pharmacovigilance and drug safety of the huge fines paid under the U.S. False Claims Act relating to the defrauding of governmental programs also receive careful attention – these fines are playing an important role in changing the landscape for pharmaceutical safety.
